Our investigation into the prostate tumor microenvironment is now out in Nature Comms: https://t.co/RGH9XdKo9B
We combined publicly available scRNA-seq data with in-house spatial transcriptomics samples to jointly anayze data from 120 patients. Here’s what we found �� 1/6
Privileged seeing the @ProBioTrial published in @NatureMedicine
My sincerest gratitude for all the dedicated doctors, nurses, lab personnel, trial managers, and most importantly, the patients who made this possible🙏
Thank you @komop_tgkanker for making ProBio possible in🇧🇪
Proud of our work from the Boston Lab on RT after neoadjuvant treatments in high-risk localized PCa: adjuvant RT rarely used and outcomes of both adjuvant and salvage poor. Patient selection will be key!
Outcomes of adjuvant and salvage RT in patients who have received neoadjuvant ARPI prior to RT for high-risk prostate cancer: our pooled analysis of trial patients published in #Prostatejournal - https://t.co/6IGw0RCCey
🔬 #PROpel unveiled PARP-inhibitors potential in #PCa, unveiling new potential synergies beyond HRRm!
🎯 More trials are needed for validation beyond pre-clinical data and pinpointing the ARSI + PARPi synergy in non-HRRm patients!
@joniau@WoutDevlies
https://t.co/8tm40k2Ee7
Find out @AttardLab’s latest publication (https://t.co/c6HZ7WgBgU) showing that lethal prostate cancer progresses to lethal disease via a limited number (two or three) of dominant clones, each harbouring patient-specific androgen receptor gene architectures.
Very proud to present the ARNEO study published in @EUplatinum!!
In high-risk PCa patients, neoadjuvant degarelix plus apalutamide prior to RP results in significantly improved pathological response compared to degarelix alone!
@joniau
A thread🧵👇:
https://t.co/6JG17AiV5u
Excited to share our new work on clinical enzalutamide resistance and lineage plasticity (LP) in prostate cancer through the @SU2C_PCF_WCDT out now in @NatureComms!
https://t.co/ZESxq082OP
@UMRogelCancer, @UMichCancBio, @umichrna, @PCF_Science, @DRSNmoonshot
Congrats Diogo to a very interesting set of neoadjuvant treated PCa, nicely complementary to our ARNEO study. Excited to see your future work. @MolendoKUL@joniau@devos_gaetan
A very interesting read from our collaborators on liquid biopsy testing in prostate cancer: PCF select is a panel to watch! #prostatecancer@joniau@MolendoKUL
Congrats to my colleague @DeBruynHelene for her passionate invited talk at @BIDMChealth@Harvard about developing murine models to truly investigate bladder function. Both invasive and non invasive models were welcomed with enthusiasm! @EveraertsW@licr_leuven